Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023

Immunovant, Inc.

2024-Q1 EPS reported -$0.57

Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.
R&D expenses rose to $50.6M (from $28.4M) driven by IMVT-1402 development and batoclimab milestones.
IMVT-1402 Phase 1 single-ascending dose data expected Sept 2023; multiple-ascending dose data Oct/Nov 2023.
Batoclimab Phase 3 MG data H2 2024; Phase 3 TED data H1 2025; CIDP Phase 2b initial data H1 2024; GD proof-of-concept Q4 2023.
Acquired IPR&D expenses $12.5M from batoclimab milestone achievement under HanAll agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported fiscal first quarter ended June 30, 2023 results: net income Net loss was $73.9 million ($0.57 per common share), EPS $0.57 per common share.

Period: fiscal first quarter ended June 30, 2023
Net income: Net loss was $73.9 million ($0.57 per common share)
EPS: $0.57 per common share
Result: reported results

Exact text from the filing

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-23-000090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.